FYARRO for Perivascular Epithelioid Cell Neoplasm (PEComa): Market Size, Forecast, and Market Insights 2019-2032 - Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
05 avr. 2024 04h39 HE
|
Research and Markets
Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "FYARRO Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...
mTOR Inhibitors Market Report 2024: A $9.3 Billion Market by 2028, Driven by Increased Adoption in Oncology, Innovations in Transplantation Medicine and a Spike in Clinical Research into Efficacy
31 janv. 2024 09h23 HE
|
Research and Markets
Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "mTOR Inhibitors Global Market Report 2024" has been added to ResearchAndMarkets.com's offering. The global market for mTOR inhibitors is witnessing...
Projected Market Value: mTOR Inhibitors Market Set to Reach $8.76 Billion by 2027 with Novartis and Pfizer in the Lead
20 sept. 2023 04h38 HE
|
Research and Markets
Dublin, Sept. 20, 2023 (GLOBE NEWSWIRE) -- The "mTOR Inhibitors Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global mTOR inhibitors market is on a...
Global mTOR (Mammalian Target of Rapamycin) Inhibitors Markets, 2022-2030 with 2021 as the Base Year - Increasing Product Approvals from Regulatory Bodies is Expected to Drive Growth
15 juin 2022 08h18 HE
|
Research and Markets
Dublin, June 15, 2022 (GLOBE NEWSWIRE) -- The "mTOR Inhibitors Market, by Drug Type, By Indication, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and...
Global PARP Inhibitors Cancer Therapy Market Outlook 2022-2028: PARP Inhibitors have Proved to be a Commercial Success in the Modern Cancer Therapeutic Segment
08 juin 2022 04h43 HE
|
Research and Markets
Dublin, June 08, 2022 (GLOBE NEWSWIRE) -- The "Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's...
Palvella Therapeutics Announces $10 Million in Funding from Ligand Pharmaceuticals to Accelerate PTX-022 through Phase 2/3 Clinical Study in Pachyonychia Congenita
18 déc. 2018 08h00 HE
|
Palvella Therapeutics
Wayne, PA, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for...
Palvella Therapeutics Announces FDA Fast Track Designation for PTX-022 for Treatment of Pachyonychia Congenita
12 nov. 2018 08h00 HE
|
Palvella Therapeutics
Wayne, PA, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for...
Palvella Therapeutics Appoints Rare Disease Senior Executive Elaine J. Heron, PhD to Board of Directors
05 sept. 2018 08h00 HE
|
Palvella Therapeutics
Wayne, PA, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for...
Cerulean Reports Third-Quarter 2014 Corporate Highlights and Financial Results
13 nov. 2014 16h06 HE
|
Daré Bioscience, Inc.
CAMBRIDGE, Mass., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Cerulean Pharma Inc. (Nasdaq:CERU), a leader in Dynamic Tumor Targeting™, today provided an update on corporate activities during the quarter...
Novogen's NV-128 Is a Unique Inhibitor of mTOR Dephosphorylation Leading to Caspase Independent Death in Chemoresistant Cancer Cells
15 avr. 2008 17h25 HE
|
Novogen, Limited
SAN DIEGO, CA--(Marketwire - April 15, 2008) - Pre-clinical studies reviewed during an oral
presentation here today at the annual meeting of the American Association
for Cancer Research demonstrate...